Biocept, Inc. (BIOC)

NASDAQ: BIOC · IEX Real-Time Price · USD
1.52
-0.02 (-1.17%)
May 18, 2022 1:00 PM EDT - Market open
Market Cap25.73M
Revenue (ttm)61.25M
Net Income (ttm)-2.82M
Shares Out16.90M
EPS (ttm)-0.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,034
Open1.56
Previous Close1.54
Day's Range1.51 - 1.58
52-Week Range1.43 - 4.97
Beta0.48
AnalystsBuy
Price Target9.69 (+536.7%)
Earnings DateMay 18, 2022

About BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSC...

IndustryBiotechnology
IPO DateFeb 5, 2014
CEOMichael Nall
Employees177
Stock ExchangeNASDAQ
Ticker SymbolBIOC
Full Company Profile

Financial Performance

In 2021, Biocept's revenue was $61.25 million, an increase of 123.04% compared to the previous year's $27.46 million. Losses were -$2.82 million, -84.14% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BIOC stock is "Buy." The 12-month stock price forecast is 9.69, which is an increase of 536.66% from the latest price.

Price Target
$9.69
(536.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q f...

1 day ago - Business Wire

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...

1 month ago - Business Wire

Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 3...

1 month ago - Business Wire

Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and c...

1 month ago - Business Wire

Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.

2 months ago - Business Wire

Biocept Appoints Philippe Marchand as Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Biocept names Philippe Marchand as new Chief Operating Officer to oversee strategic business operations, including its CNSide CSF assay.

2 months ago - Business Wire

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Developme...

SAN DIEGO--(BUSINESS WIRE)--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.

2 months ago - Business Wire

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interi...

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim Presiden...

3 months ago - Business Wire

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

SAN DIEGO--(BUSINESS WIRE)--Biocept names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.

3 months ago - Business Wire

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CLIA_Lab--Biocept has received more than 765,000 samples for RT-PCR COVID-19 testing since June 2020.

3 months ago - Business Wire

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company...

4 months ago - Business Wire

Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that h...

SAN DIEGO--(BUSINESS WIRE)--SABCS Spotlight Presentation shows that Biocept's CNSide CSF assay identifies actionable HER2 mutations in metastatic breast cancer.

5 months ago - Business Wire

Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diag...

SECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYS...

Other symbols:DGX
5 months ago - PRNewsWire

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

SAN DIEGO--(BUSINESS WIRE)--Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.

5 months ago - Business Wire

CORRECTING and REPLACING Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects...

SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

5 months ago - Business Wire

Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in...

SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

6 months ago - Business Wire

Biocept Reports Third Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended Septembe...

6 months ago - Business Wire

Study Shows Biocept's Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays i...

SAN DIEGO--(BUSINESS WIRE)--Published abstract shows Biocept's Switch-Blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.

6 months ago - Business Wire

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nin...

6 months ago - Business Wire

Biocept to Present at the LD Micro Main Event on October 13

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #LD_Micro--Biocept to present at LD Micro Main Event

7 months ago - Business Wire

Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10% an...

7 months ago - Benzinga

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Stu...

SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.

7 months ago - Business Wire

7 of the Best Penny Stocks to Buy Coming Into Year-End

These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared firs...

Other symbols:BOXLEBONEMANMNMDXELA
7 months ago - InvestorPlace

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to...

SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.

7 months ago - Business Wire